From the FDA Drug Label
The FDA drug label does not answer the question.
From the Research
The most effective approach for preventing venous thromboembolism (VTE) in acutely ill medical patients is extended thromboprophylaxis with betrixaban, as demonstrated by the study DOI: 10.1056/NEJMoa1607141, which showed a significant reduction in VTE events compared to standard enoxaparin, particularly in patients with elevated D-dimer levels or those aged 75 years or older 1.
Key Findings
- The study DOI: 10.1056/NEJMoa1607141 compared extended thromboprophylaxis with betrixaban (80 mg once daily for 35-42 days) to standard enoxaparin (40 mg once daily for 10±4 days) in preventing VTE in acutely ill medical patients.
- Betrixaban showed a significant reduction in VTE events compared to enoxaparin, particularly in patients with elevated D-dimer levels or those aged 75 years or older.
- The recommended regimen is betrixaban 160 mg loading dose on day 1, followed by 80 mg once daily for 35-42 days.
- For patients with severe renal impairment (creatinine clearance 15-30 mL/min) or those taking P-glycoprotein inhibitors, the dose should be reduced to 80 mg loading dose followed by 40 mg daily.
Comparison with Other Studies
- A study published in 2022 compared the effectiveness and safety of ceftriaxone to standard of care for treatment of bloodstream infections due to methicillin-susceptible Staphylococcus aureus, and found that ceftriaxone was not statistically different from standard of care in terms of clinical cure, microbiological cure, and mortality 2.
- Another study published in 2023 found that definitive treatment with ceftriaxone was associated with a higher risk of treatment failure within 90 days compared to cefazolin or antistaphylococcal penicillins in patients with MSSA bacteremia 3.
Conclusion Not Applicable
Instead, the focus is on the most recent and highest quality study, which is the study DOI: 10.1056/NEJMoa1607141, and its findings on the effectiveness of betrixaban in preventing VTE in acutely ill medical patients.
Additional Considerations
- The study DOI: 10.1056/NEJMoa1607141 highlights the importance of extended thromboprophylaxis in preventing VTE in acutely ill medical patients, particularly in those with elevated D-dimer levels or those aged 75 years or older.
- The use of betrixaban for extended thromboprophylaxis is supported by its longer half-life and minimal renal clearance, making it a suitable option for this population.
- Further studies are needed to confirm the findings of the study DOI: 10.1056/NEJMoa1607141 and to explore the potential benefits and risks of extended thromboprophylaxis with betrixaban in different patient populations.